studying the senescent t cell features and its relationship with the chemotherapy efficacy in young tnbc

Conditions: T-Cell Dysfunction; Chemotherapy Effect; Adverse Events

Summary: the goal of this observational study is to learn about the features of senescent t lymphocytes induced by chemotherapy and its relationship with the efficacy of neoadjuvant chemotherapy in young triple-negative breast cancer (tnbc) patients. the main questions it aims to answer are: * what are the senescent features of peripheral t lymphocytes in young tnbc patients receiving neoadjuvant chemotherapy and the relationship with the efficacy of neoadjuvant chemotherapy? * what is the relationship between senescent t cells and adverse events, dfs and tumor infiltrating lymphocytes? 1. participants will receive 6 cycles of docetaxel + adriamycin/epirubicin + cyclophosphamide (tec/tac) neoadjuvant chemotherapy, and radical mastectomy after chemotherapy. 2.5ml peripheral venous blood will be collected before chemotherapy, after 2 cycles of chemotherapy, before surgery, and six months after surgery. 3.clinicopathological data, chemotherapy-related adverse events and prognostic information of patients should be collected during the study.

this is a single-center observational study that is expected to enroll 30 breast cancer patients and 10 controls from july 2023 to june 2026. we mainly want to investigated senescent t lymphocytes characteristics during neoadjuvant chemotherapy in young triple-negative breast cancer patients. besides, the relationship between senescent t lymphocytes and neoadjuvant chemotherapy efficacy also of concern to us. inclusion criteria: (1) female, age ≤40 years old; (2) invasive breast cancer was confirmed by puncture pathology and tnbc (er-, pr-, her2-) was confirmed by immunohistochemistry; (3) patients who meet the indications of neoadjuvant chemotherapy prescribed in the guidelines. exclusion criteria: (1) iv patient or history of other malignant tumors; (2) recently infection or autoimmune disease is not cured or hbv, hiv positive; (3) had a history of surgery 3 months before enrollment; (4) patients with insufficient clinicopathological data; (5) those who do not meet the evidence of neoadjuvant chemotherapy or are unwilling to cooperate. withdrawal criteria: (1) the subjects did not receive radical surgery in our hospital or were unwilling to continue to participate in the follow-up study; (2) termination of chemotherapy due to serious side effects or disease progression during chemotherapy; (3) research data related to the experiment is missing and cannot be supplemented; (4) poor specimen quality (hemolysis, contamination, etc.); (5) follow-up lost. participants will receive 6 cycles of tec/tac neoadjuvant chemotherapy, and radical mastectomy after chemotherapy. clinicopathological data, chemotherapy-related adverse events and prognostic information of patients should be collected during the study. 5ml peripheral venous blood will be collected before chemotherapy, after 2 cycles of chemotherapy, before surgery, and six months after surgery. the senescence phenotype of t lymphocytes will be determined by flow cytometry. the main purpose are: * studying the senescent features of peripheral t lymphocytes in young tnbc patients receiving neoadjuvant chemotherapy and the relationship with the efficacy of neoadjuvant chemotherapy. * studying the relationship between senescent t cells and adverse events, dfs and tumor infiltrating lymphocytes.

Eligibility criteria:
inclusion criteria: 1. female, age≤40 years old, 2. invasive breast cancer confirmed by pathology, immunohistochemistry showed tnbc (er-, pr-, her2-), 3. indications for neoadjuvant chemotherapy according to guidelines: tumor diameter \> 2cm or with axillary lymph node metastasis or desiring breast-conserving surgery but should obtain negative surgical margins through neoadjuvant chemotherapy. exclusion criteria: 1. stage iv patients or a history of other malignancies, 2. having microbial infection or autoimmune disease have not been cured or having hbv, hiv infection, 3. having surgery 3 months before enrollment, 4. patients with insufficient clinicopathological data, 5. does not meet the indications for neoadjuvant chemotherapy or is unwilling to cooperate.

Keywords: breast cancer senescence chemotherapy